Latest Commercial Readiness News

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Nanoveu Limited reports strong momentum in its EyeFly3D technology with a significant purchase order and launches an AI-powered app, while advancing its strategic acquisition of semiconductor innovator EMASS.

NGX Limited reports significant progress in its uranium exploration in Namibia and graphite development in Malawi, alongside strategic leadership changes and a strong financial position.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Livium and Mineral Resources have agreed to extend their joint development agreement, funding additional optimisation activities for the LieNA® lithium extraction technology and setting the stage for a 50/50 joint venture.